Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst ...

There will be an additional pool of potential users who are not insulin-dependent but would like to use a wearable like Stelo or G7, but in order to meet this demand, Dexcom may have to adjust its ...

is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the ...

DexCom (DXCM) shares are down on Monday morning on a notification that some customers are receiving 30 days of supplies instead of 90 days amid ...